Shirit Einav MD
Associate Professor, Medicine - Infectious Diseases, Stanford University Medical Center
Join to View Full Profile
300 Pasteur DrPalo Alto, CA 94304
Phone+1 650-723-4000
Dr. Einav is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Stanford Health Care-Sponsored Stanford UniversityFellowship, Infectious Disease, 2004 - 2006
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1999 - 2002
Tel Aviv University SacklerClass of 1998
Certifications & Licensure
CA State Medical License 2002 - 2026
MA State Medical License 2001 - 2006
American Board of Internal Medicine Infectious Disease
Publications & Presentations
PubMed
- Development of pyrazolo[1,5-a]pyrimidine based macrocyclic kinase inhibitors targeting AAK1.Theresa E Mensing, Christian G Kurz, Jennifer A Amrhein, Theresa A L Ehret, Franziska Preuss
European Journal of Medicinal Chemistry. 2025-12-05 - Discovery of antivirally active inhibitors of adaptor protein-2 associated kinase 1 based on various bicyclic heteroaromatic scaffolds derived from a 7-azaindole analo...Stijn Anthonissen, Wout Van Eynde, Marwah Karim, Ling-Jie Gao, Do Hoang Nhu Tran
European Journal of Medicinal Chemistry. 2025-12-05 - Comprehensive metabolomics combined with machine learning for the identification of SARS-CoV-2 and other viruses directly from upper respiratory samples.Catherine A Hogan, Anthony T Le, Afraz Khan, LingHui David Su, ChunHong Huang
Journal of Clinical Microbiology. 2025-10-09
Press Mentions
Test Can Predict Severe Dengue Infection, Study FindsMarch 29th, 2022
Gene Pattern Predicts Sickness from Dengue VirusFebruary 5th, 2019
Set of Genes Predicts Severity of DengueJanuary 29th, 2019- Join now to see all
Grant Support
- Advancing the development of a novel class of small molecules for treating pan-coronavirus infectionsSTANFORD UNIVERSITY2021–2026
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
